EVALUATION OF THE GLYCOREGULATION EFFICACY BEFORE AND AFTER TREATMENT WITH INSULIN DEGLUDEC IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE REPUBLIC OF NORTH MACEDONIA
Valentina VELKOSKA NAKOVA, Zoran NAKOV, Ruzica JANEVA, Cvetanka VOLKANOVSKA ILIJEVSKA
Abstract
Patients with type 2 diabetes mellitus (T2DM) who have unsatisfactory glycoregulation with concurrent use of basal insulin and oral hypoglycemics, should be switched to a more intensive therapy regime. To evaluate the efficacy of newly available insulin degludec 70/insulin aspart 30 (IDegAsp), we retrospectively analyzed glycoregulation in 131 patients with T2DM treated with this insulin. All 131 patients were with unsatisfactory glycoregulations, and were switched to IDegAsp from other insulins (except basal-bolus insulin regimen). After a mean period of 11.75±5 months of the treatment with IDegAsp, we found statistically significant improvement in fasting and postprandial glucose levels, and HbA1c (12.5±4.4 vs. 8.8±3.9mmol/l, 13.2±4.6 vs. 9.6±4.1mmol/l, 9.7±1.8 vs. 8.1±1.6%, p<0.01, respectively). The total average daily dose of insulin units (IU) was the same, and there weren’t statistically significant differences in the frequency of hypoglycaemia (p<0.05). From the results, we can conclude that patients with T2DM, who switched to IDegAsp from previous antidiabetic insulin treatment (except basal-bolus insulin regimen) had improved glycaemic control without increased insulin units, and without higher risk for hypoglycemia.
Pages:
237 - 242